About

I am an award-winning writer, editor, photographer and designer with more than 30 years of experience in the media. After studying at the University of Leeds, then London and Anglia HEC, I moved to Canada in the 1980s and started out on the radio while also writing for various music and sports publications, and doing freelance photography. I then edited some magazines before working at a science organization, doing communications and editing publications in a programming language called LaTeX that was challenging but exciting.

Following that, I edited a newspaper, spent some time in the US, and then moved back to the UK where I edited a food B2B publication.
I’ve written, and taken photographs for, hundreds of publications around the world, as well as for books, album covers, DVDs, and shot coverage for documentaries. I’ve edited books, written nine of my own, and done redesigns for several publications. And now I’m writing about biotech, as well as creating videos and a weekly podcast.

I’ve done other things, like running an aquarium, teaching photography and drumming (not at the same time), and running football (soccer) refereeing courses.

In what spare time I have, I love spending time with my wife, son and dog, challenging hikes up the Scottish hills (and down again), playing and writing music, watching baseball and soccer, and collecting memorabilia and autographs.

Articles by Jim Cornall

Investment in Hyperthermics’ process to turn biowaste into energy and proteins

Boost for dementia gene-based therapies

Beyond Biotech podcast 1: Forbion, OMass, PharNext

Gimv creates new fund for life science companies

Molecular farming company Moolec Science joins with LightJump to list on Nasdaq

Clean and green: Unilever and Geno launch $120m palm oil alternatives venture

ADVERTISEMENT

TILT Biotherapeutics raises $10M to push ahead on cancer immunotherapies

Sling Therapeutics emerges with $35M to tackle thyroid eye disease

Eurocine Vaccines expands portfolio to develop HSV-2 vaccine

Biotech companies to benefit from Third Rock Ventures $1.1B fund

NZ biotech company develops Johne’s Disease assay

Biotech Acquisition Company and Blade Therapeutics merger collapses

ADVERTISEMENT